Highlights
-
•
Autoimmune encephalitis is a disease condition which presents with refractory seizures in children requiring immunotherapy.
-
•
KD is a non-pharmacological treatment modality used worldwide in people with drug-resistant epilepsy. It acts through many anti-inflammatory mechanisms leading to seizure control.
-
•
This article highlights the use of adjuvant effect of ketogenic diet in anti GAD-65 antibody positive autoimmune encephalitis.
-
•
It is the need of the hour to formulate treatment protocols incorporating newer treatment strategies including KD.
Keywords: Classic ketogenic diet, Super refractory status epilepticus, Autoimmune encephalitis
Abbreviations: ASM, Anti-seizure medications; GAD, Glutamic acid decarboxylase; AIE, Autoimmune encephalitis
Abstract
Autoimmune encephalitis refers to a spectrum of inflammatory brain diseases which can present as drug-resistant seizures in children. Hereby, we report a case of anti-GAD-65 antibody encephalitis in a 7-year-old child who presented with superrefractory status epilepticus (SRSE). The traditional management with multiple anti-seizure medications at appropriate dosage and immunotherapy was tried despite which the child continued to have seizures. Hence the child was initiated on a classic ketogenic diet. He achieved ketosis within 48 h of diet initiation and there was a drastic reduction in the seizure frequency followed by a completed remission. Hence, this non-pharmacological intervention was an effective adjunct in achieving seizure control in our patient. A ketogenic diet has been sparingly used for the management of post-encephalitic epilepsy and autoimmune epilepsy. However, the data onthe effectiveness of the ketogenic diet in the management of autoimmune encephalitis is scarce. Starting KD early in the disease course helped not only in seizure control but also preserved the cognitive and neurological well-being of the child.
1. Introduction
Autoimmune encephalitis (AIE) in children usually presents with behavioral changes, drug-resistant seizures, and encephalopathy. Though anti-NMDA receptor antibody is the most common antibody associated with AIE, anti-VGKC antibodies, anti-GABA receptor antibodies, anti-GAD-65 antibodies and others have also been reported in children besides several cases of seronegative AIE [1]. We report a case of anti-GAD65-Ab AIE in a 7-year-old child with superrefractory status epilepticus (SRSE) in whom seizure control could not be achieved despite multiple anticonvulsants and immunotherapy. This case report focuses on the role of a non-pharmacological intervention namely the ketogenic diet which was used to augment the treatment. The management challenges faced during the prolonged duration of hospital stay will be highlighted.
2. Csase summary
A 7-year-old developmentally normal boy presented to the emergency room with a low-grade fever of 5 days duration followed by multiple episodes of seizures. The seizure semiology included lip-smacking movements and right upper limb tonic-clonic movements lasting for around 2 min. His sensorium wasnormal during the period in between the seizures. The child was given intravenous (IV) loading doses of multiple anti-seizure medications (ASM) (in the order of sequence) including levetiracetam(60 mg/kg/day), sodium valproate(60 mg/kg/day), phenytoin(8 mg/kg/day), lacosamide (8 mg/kg/day), clobazam(1.2 mg/kg/day), oxcarbazepine(40 mg/kg/day) and Midazolam infusion at optimal dosages despite which the seizures persisted. Preliminary work up with cerebrospinal fluid (CSF) analysis and magnetic resonance imaging (MRI) of the brain with gadolinium contrast were unremarkable.CSF showed no cells, glucose of 71 mg/dl, and proteins of 22.7 mg/dl.Electroencephalogram (EEG) showed bilateral diffuse background slowing suggestive of cerebral dysfunction. Refractory status epilepticus treatment protocol was followed and the child was continued on multiple ASMs, midazolam infusion, intravenous Immunoglobulin (IVIg) (400 mg/kg/day) for 5 days, and IV pulse methylprednisolone (30 mg/kg/day) for 5 dayswere given, despite these measures, seizure control could not be achieved. The seizure frequency quadrupled from 3 to 4 episodes/day to 15–20 episodes/day of focal onset seizures. Given persistent seizures and a decline in the Glasgow coma scale, the child was intubated and put on mechanical ventilation. He was then transferred to our hospital. He was on six ASMs at maximally tolerated dosages. The switch from levetiracetam to brivaracetam marginally reduced the seizures to nearly 10 episodes a day. An 18-FDGPET-CT (fluorodeoxyglucose-positron emission tomography) of the brain showed hypometabolic changes involving bilateral temporal and parietal lobes. CSF oligoclonal bands, anti-TPO antibodies, ANA, and anti-NMDAR antibody titers were negative. While serum and CSF GAD-65Ab were positive (serum GAD-65 antibody titre: 221 IU/ml(0–17) and CSF GAD-65 AB titre:218 IU/ml [0–17]). Hence a diagnosis of anti-GAD-65 Ab-associated AIE was made. On day 7, second-line immunomodulation therapy with rituximab (750 mg/m2) was given. Since maximal doses of ASM, adequate first-line immunotherapy, and second-line immunomodulation did not achieve seizure control, a non-pharmacologic therapy in the form of a customized 4:1 proportion classic ketogenic diet (KD) was initiated. A non-fasting protocol was followed.Regular monitoring in the form of serial nutritional assessment, blood sugars, blood gas, and urinary ketones was done. A day after initiation of KD only traces of the urine ketones were found.Within 48 h of KD initiation, the child achieved adequate ketosis(2 + ), and the seizure frequency was drastically reduced. The drug levels of the ASMs were checked periodically and dosages were adjusted accordingly. After 12 days of ventilator support and more than 72 h of complete seizure freedom, the child was extubated. KD was continued and tapering of ASMs sequentially was started. The clinical course of the child is depicted in Fig. 1 Seizure frequency depicted in Fig. 2.
Fig. 1.
Graphic representation of the in-hospital clinical course. ASMs: anti-seizure medications. KD: ketogenic diet. EEG: electroencephalogram. IVIg: Intravenous immunoglobulin. GCS: Glasgow coma scale.
Fig 2.
Seizure frequency during hospitalisation.
A mini-mental status examination was done serially to objectively assess the higher mental functions, which showed a steady and gradually improving trend. The degree of disability and dependence were assessed weekly using the modified Rankin scale. The ketogenic diet was continued for three more months after his discharge and was slowly tapered and stopped over the next 3 months. Currently,the child is only on brivaracetam (1 mg/kg/day), lacosamide (4 mg/kg/day) and clobazam (0.3 mg/kg/day) and on regular follow-up once a month. He is now able to attend regular school with a good scholastic performance and has no sleep or neurobehavioral issues. The child had 2 brief breakthrough seizures, nearly-one-year after discharge which were triggered by fever and lack of sleep. His Modified Rankin scale was 1 at the last follow-up visit.
3. Discussion
Autoimmune encephalitis is a significant cause of encephalopathy in children [2]. Early initiation of appropriate immunosuppressive therapy leads to good cognitive and neurodevelopmental outcomes. In a review by Cellucci et al, the typical clinical features in children with anti-GAD encephalitis include memory loss, cognitive impairment, cerebellar ataxia, and temporal lobe seizures [3]. However, our child did not have memory loss or cerebellar ataxia.
Majority of children with autoimmune encephalitis present with seizures in the form of status epilepticus (SE) or super refractory status epilepticus (SRSE). SRSE is the SE that fails to terminate more than 24 h of anesthetic infusion or recurs on weaning of the infusion.This child also presented with SRSE following a mild prodromal illness.
In a study by Lilleker et al of 112 patients with unexplained adult-onset patients, 6 patients had high titers of anti-GAD Ab positivity, and all 6 of them presented with focal seizures [4].
The treatment modalities available for the management of pediatric AIEare highly variable and patient-specific and include the usage of immunotherapy along withASM whenever indicated. This child presented with SRSE which was not controlled even on multiple ASMs and benzodiazepine infusion. Since complete seizure freedom and preservation of the neuro-cognitive status of the child was our ultimate goal, a classic ketogenic diet (KD) was attempted in addition to the rational usage of ASM and immunotherapy. The literature on the role of early KD therapy in pediatric AIE is scarce although its use in post-encephalitic epilepsy has been described [5].
KD is a non-pharmacological treatment modality used worldwide in people with drug-resistant epilepsy [6]. The exact mechanisms by which KD exerts an anti-seizure effect are still under investigation. Many anti-inflammatory mechanisms of KD have been proposed. Majorly KD improves mitochondrial function and decreases oxidative stress. One of the major ketone bodies namely B-hydroxybutyrate has been shown to reduce the production of reactive oxygen species (ROS), improving mitochondrial respiration. It also stimulates the cellular endogenous antioxidant system with the activation of nuclear factor erythroid-derived 2-related factor 2 (Nrf2) and modulates the ratio between the oxidized and reduced forms of nicotinamide adenine dinucleotide (NAD+/NADH). Furthermore, the ketogenic diet performs anti-inflammatory activity by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and leucine-rich-containing family thereby improving memory encoding [7].
KD is a long chain triglyceride-based, low carbohydrate diet. A classic 4:1 ketogenic ratio means 4 g of fat for every-one gram of protein and carbohydrate. Modified Atkins Diet (MAD) is one in which the ketogenic ratio is 1:1 which is usually home regulated [8]. In the absence of glucose, the brain utilizes ketone bodies as the fuel source [9]. Due to various mechanisms, itleads to an increase in GABAergic and a decrease in glutaminergic transmission leading to reduced neuronal excitabilityresulting in anti-epileptic action.The majority of children achieve a significant reduction in seizure burden on KD.
Febrile infection-related epilepsy syndrome (FIRES) is a form of pseudo-encephalitic epileptic encephalopathy that presents with drug-resistant status epilepticus in developmentally normal healthy children [10]. Treatment of FIRES with anti-seizure medications like phenobarbital, topiramate, immunoglobulin, steroids, and plasmapheresis has got limited success [11]. In such children, KD proves to be more effective as per a paper by Singh et al [12].
In a case series of ten patients by Husari et al, MAD was used in patients with post-encephalitis (PE) and autoimmune associated epilepsy (AAE) with a 70 % responder rate and more than 50 % reduction in seizures [5].The study concluded that KD therapies may be feasible and safe in the management of chronic PE and AAE. In our child, classic 4:1 KD was successfully used for achieving seizure remission in anti-GAD65 encephalitis.
KD may be effective for the management of seizures in autoimmune associated epilepsy and post encephalitis because of the anti-seizure properties and also by anti-inflammatory mechanisms of action. This could explain the high response rate seen in the patients [5].
Many prospective and retrospective studies have been done to evaluate the use of KD in the treatment of SRSE of various etiologies. But most of these studies are adult based. A few studies have reported the effectiveness of KD for management of SRSE in paediatric patients due to various etiologies specifically FIRES [[13], [14]]. In a case report with literature review by Prasoppokakorn et al, medium chain triglyceride based KD was reported to be beneficial in young adult patients with SRSE and AI encephalitis [15]. However to the best of our knowledge no study reports the utility of KD in autoimmunity mediated SRSE in a child which makes this case report unique in its own way.
In a Saudi Arabian-based study by Ali HA et al, the benefits of a non-fasting protocol of ketogenic diets have been described. In their study, 16 children with drug-resistant epilepsy were chosen and all were hospitalized and started on KD either by the oral or nasogastric route. It concluded that nine (56 %) children experienced significant seizure improvement within 3 days of starting KD, with three children becoming seizure-free during the KD. Hence it was suggested that a non-fasting KD protocol is a safe and effective option for children with intractable epilepsy [16].
Data extrapolated from children suggests that most responders experience a reduction in seizures on KD within 14 days from initiation of the diet [17]. However, in our case, the child had a significant reduction in seizure frequency in just 48 h after initiation of KD.
To achieve complete clinical and electrographic seizure freedom, the ketogenic diet was used as an adjunct which turned out to be successful. The cognitive status of the child was preserved probably due to aggressive management early in the course of the disease.
This case report highlights the role of the utility of the classic ketogenic diet as an adjunct to ASM in children who fail to respond to immunotherapies in successfully managing a child with SRSE and anti-GAD65-Ab AIE. The child is on regular follow-up for more than a year. A serial clinical examination with developmental assessment is being performed at every visit. He remains seizure-free and can attend regular school with good scholastic performance. His Modified Rankin score was 1 at the last follow-up.
4. Lsimitations
This is a single case report based on a retrospective review. The natural history of SRSE in children would have been more evident in a case series. Serum ketones were not done and serial EEG monitoring could not be performed which we quote as limitations to our study.
5. Review of literature
A brief review of literature about the management of anti-GAD-65 Ab encephalitis in children is summarized in Table 1. It can be inferred that a trial of KD was not reported in any of them. This literature review shows that the management of anti-GAD 65 Ab encephalitis in children can be highly variable. The table below contains the summary of reported cases of pediatric anti-GAD-65 autoimmune encephalitis.
Table 1.
| AUTHOR AND YEAR | AGE/SEX | PRESENTATION | MRI | EEG | ANTI GAD | TREATMENT | OUTCOME |
|---|---|---|---|---|---|---|---|
| Nedia Ben Achow 2018 | 9y/F | -refractory seizures -behavioural disturbances -severe intractable autonomic disturbances → dysrhythmia, tachy/bradycardia, increased or reduced BP, hypo/hyperthermia |
MRI normal | EEG showed slowed theta rhythm and bilateral fronto temporal spike wave discharges | Anti GAD65 antibody positive | Two doses of IVIG Methyl prednisolone Rituximab |
-Died due to Autonomic dysfunction after onset (fatal dysautonomia) |
| Haberlandt 2014 | 8y/F | -Behavioural changes | MRI normal | Temporal lobe epilepsy | Anti GAD65 antibody positive | Steroids IVIG |
Restitution |
| Farunk Incicek 2014 | 7y/M | -behavioural changes -drowsiness -preceding URI a week prior -MRI normal -EEG bilateral temporal epileptiform abnormalities -All infective workup negative |
MRI brain normal | Bilateral temporal epileptiform abnormalities |
Serum anti-GAD highly positive | Levitracetam IVIG Plasma exchange IVIG |
Improved |
| Chanhong Ren 2021 | 6y/F | -seizures -headache -memory deficit |
MRI brain normal | EEG right sided epileptiform discharges |
-Serum GAD 1:100CBA and CSF 1:320CBA |
IVIG Methyl prednisolone Oral steroids |
Refractory focal seizures |
| Chanhong Ren 2021 | 16y/F | -seizures -memory deficit -depression -dysautonomia –On 5 year followup parenchymal atrophy |
MRI B/L hippocampal changes | EEG slowed theta rhythm with bilateral temporal spike wave discharges |
-Serum GAD 1:32CBA and CSF 1:32CBA |
IVIG Methyl prednisolone Oral steroids Rituximab |
Persistent memory impairment and refractory focal seizures |
| Chanhong Ren 2021 | 4y9m/F | -vomiting, headache, confusion |
MRI normal | EEG showed slowed theta rhythm | -Serum GAD 1:100CBA and CSF 1:320CBA |
IVIG Methyl prednisolone Oral steroids |
Complete recovery |
| Olson JA 2002 | 6y/M | -epilepsia partialis continua, apahsia |
MRI gray matter changes |
EEG showed left sided epileptiform discharges and slowing |
Serum GAD 19610U/ml and CSF 3325U/ml |
High dose steroids IVIG Plasma exchange |
Seizure free |
| Akman CI 2009 | 16y/F | -focal seizures and status epilepticus -declining academic performance |
-EEG shows bilateral temporal abnormalities |
Serum and CSF GAD greater than 300 IU/ml | Methyl prednisolone IVIG |
Refractory seizures | |
| Korff CM 2011 | 2y/F | -refractory seizures, memory impairment, developmental regression, ataxia |
-MRI normal |
-EEG shows multifocal discharges and right frontal seizures |
-Serum GAD 3400 IU/ml and CSF 13U/ml |
Methyl prednisolone Plasma exchange MMF Rituximab |
Clinical improvement but had refractory seizures |
| Bigis 2015 | 15y/M | -headache, memory disturbances, seizures, behavioural change |
-MRI showed mildly increased signal in left amygdala and right hippocampus |
-EEG shows interictal epileptiform discharges arising from right frontotemporal region | -Serum GAD 1:160000CBA and CSF 1:128000CBA |
IVIG Rituximab Prednisolone |
Excellent seizure control, improvement in transient global amnesia like episodes |
| Incecik F 2015 | 7y/M | -behavioural changes -drowsiness |
-MRI normal |
-EEG shows bilateral temporal epileptiform abnormalities |
-Serum and CSF GAD positive | IVIG Plasma exchange |
Complete recovery |
| Current case | 7 yr/M | Refractory seizures Lip-smacking movements and right upper limb |
MRI brain normal |
EEG diffuse background slowing |
Serum and CSF GAD positive | ASM IVIG Methyl prednisolone Rituximab Ketogenic diet |
Complete recovery |
6. Conclusion
Anti-GAD-65 Ab encephalitis is a rare entity in children and requires aggressive management in the initial stages to elicit a favorable outcome. To the best of our knowledge, this is the first case of successful termination of SRSE in a child with anti-GAD autoimmune encephalitis. It is the need of the hour to systematically study the natural course of the disease and formulate treatment protocols incorporating newer treatment strategies including KD.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
We would like to thank the PICU team, electrophysiology department, nutritionist of Sri Ramachandra Institute of Higher Education and Research, Chennai, India, and the patient's family members for their consent.
References
- 1.Hacohen Y., Wright S., Waters P., Agrawal S., Carr L., Cross H., et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry. 2013;84(7):748–755. doi: 10.1136/jnnp-2012-303807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Garg D., Mohammad S.S., Sharma S. Autoimmune encephalitis in children: An update. Indian Pediatr. 2020;57(7):662–670. [PubMed] [Google Scholar]
- 3.Cellucci T., Van Mater H., Graus F., Muscal E., Gallentine W., Klein-Gitelman M.S., et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e663. doi: 10.1212/NXI.0000000000000663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lilleker J.B., Biswas V., Mohanraj R. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure. 2014;23(8):598–602. doi: 10.1016/j.seizure.2014.04.009. [DOI] [PubMed] [Google Scholar]
- 5.Husari K.S., Cervenka M.C. Ketogenic diet therapy for the treatment of post-encephalitic and autoimmune-associated epilepsies. Front Neurol. 2021;12 doi: 10.3389/fneur.2021.624202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Kossoff E.H., Zupec-Kania B.A., Amark P.E., Ballaban-Gil K.R., Christina Bergqvist A.G., Blackford R., et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009;50(2):304–317. doi: 10.1111/j.1528-1167.2008.01765.x. [DOI] [PubMed] [Google Scholar]
- 7.Pinto A., Bonucci A., Maggi E., Corsi M., Businaro R. Anti-oxidant and anti-inflammatory activity of ketogenic diet: new perspectives for neuroprotection in Alzheimer's disease. Antioxidants (Basel) 2018;7(5):63. doi: 10.3390/antiox7050063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Sharma S., Jain P. The ketogenic diet and other dietary treatments for refractory epilepsy in children. Ann Indian Acad Neurol. 2014;17(3):253–258. doi: 10.4103/0972-2327.138471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lin K.L., Lin J.J., Wang H.S. Application of ketogenic diets for pediatric neuro critical care. Biomed J. 2020;43(3):218–225. doi: 10.1016/j.bj.2020.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Mikaeloff Y., Jambaqué I., Hertz-Pannier L., Zamfirescu A., Adamsbaum C., Plouin P., et al. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis. Epilepsy Res. 2006;69(1):67–79. doi: 10.1016/j.eplepsyres.2006.01.002. [DOI] [PubMed] [Google Scholar]
- 11.Van Baalen A., Häusler M., Plecko-Startinig B., Strautmanis J., Vlaho S., Gebhardt B., et al. Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES. Neuropediatrics. 2012;43(04):209–216. doi: 10.1055/s-0032-1323848. [DOI] [PubMed] [Google Scholar]
- 12.Singh R.K., Joshi S.M., Potter D.M., Leber S.M., Carlson M.D., Shellhaas R.A. Cognitive outcomes in febrile infection-related epilepsy syndrome treated with the ketogenic diet. Pediatrics. 2014;134(5) doi: 10.1542/peds.2013-3106. [DOI] [PubMed] [Google Scholar]
- 13.Wang X., Gao X., Lu G., Lu Z., Zhou S., Wang Y.i., et al. The ketogenic diet for paediatric patients with super-refractory status epilepticus in febrile infection-related epilepsy syndrome. Acta Epileptologica. 2020;2(1) [Google Scholar]
- 14.Breu M., Häfele C., Glatter S., Trimmel-Schwahofer P., Golej J., Male C., et al. Ketogenic diet in the treatment of super-refractory status epilepticus at a pediatric intensive care unit: A single-center experience. Front Neurol. 2021;12 doi: 10.3389/fneur.2021.669296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Prasoppokakorn T., Jirasakuldej S., Lakananurak N. Medium-chain triglyceride ketogenic diet is effective for treatment of an adult with super-refractory status epilepticus: a case report and literature review. Eur J Clin Nutr. 2019;73(12):1594–1597. doi: 10.1038/s41430-019-0471-4. [DOI] [PubMed] [Google Scholar]
- 16.Alameen Ali H., Muthaffar O., AlKarim N., et al. The efficacy of non-fasting ketogenic diet protocol in the management of intractable epilepsy in pediatric patients: a single-center study from Saudi Arabia. J Internat Med Res. 2022 doi: 10.1177/03000605221081714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kossoff E.H., Laux L.C., Blackford R., Morrison P.F., Pyzik P.L., Hamdy R.M., et al. When do seizures usually improve with the ketogenic diet? Epilepsia. 2008;49(2):329–333. doi: 10.1111/j.1528-1167.2007.01417.x. [DOI] [PubMed] [Google Scholar]


